MiniMed Group (NASDAQ:MMED) Upgraded at Zacks Research

Zacks Research upgraded shares of MiniMed Group (NASDAQ:MMED) to a hold rating in a research note published on Thursday morning,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on MMED. Morgan Stanley began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 price target for the company. Deutsche Bank Aktiengesellschaft began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 price target for the company. Mizuho began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued an “outperform” rating and a $21.00 price target for the company. Citigroup began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $23.00 price target for the company. Finally, BTIG Research began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $25.00 price target for the company. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, MiniMed Group has an average rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Price Performance

Shares of MMED opened at $13.92 on Thursday. MiniMed Group has a 1-year low of $12.80 and a 1-year high of $20.48.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.